drugset / Trial / NCT04617314
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, pharmacokinetics, and effect of RC108-ADC for injeciton in subjects with c-Met positive advanced malignant solid tumors.
Timeline
- Start
- 2021-03-10
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RC108 | Other / unclassified | 0.1 mg/kg | — |
| Subject | RC108 | Other / unclassified | 0.3 mg/kg | — |
| Subject | RC108 | Other / unclassified | 0.9 mg/kg | — |
| Subject | RC108 | Other / unclassified | 1.5 mg/kg | — |
| Subject | RC108 | Other / unclassified | 2 mg/kg | — |
| Subject | RC108 | Other / unclassified | 2.5 mg/kg | — |
| Subject | RC108 | Other / unclassified | 3 mg/kg | — |